One Size Doesn’t Fit All: Why CRO Flexibility Matters More Than Ever

In today’s clinical development landscape, no two trials, or trial Sponsors, are exactly alike. Each organization brings its own needs, priorities, and operating models to the table. For this reason, outsourcing strategies for clinical trials can vary widely. Some Sponsors prefer to engage multiple specialized vendors, selecting only the services they need to complement their internal capabilities. Others opt for a single, full-service CRO to manage the entire trial, leaning on a unified partner for seamless execution.

By |2025-12-01T17:51:56+00:00March 25th, 2025|WEP Insights|

The Importance of Having a Strong Clinical Monitoring Team When Collecting Data in an EAP

Expanded Access Programs (EAPs) allow patients with serious or life-threatening conditions to obtain investigational treatments outside of the clinical trial setting. Because they are not formal clinical trials, EAPs do not require as much data [...]

By |2025-12-01T18:01:18+00:00February 17th, 2025|WEP Insights|

The need for Harmonized Regulations in the Expanded/Early Access, Compassionate Use and Named Patient Use space

Expanded/Early Access (EA), Compassionate Use (CU) and Named Patient Use (NPU) are critical pathways for patients with serious or life-threatening conditions to obtain investigational treatments outside of clinical trials. While these programs offer hope for [...]

By |2025-12-01T17:58:57+00:00February 6th, 2025|WEP Insights|

Key Takeaways from Panel Discussion at WEF Davos – “The Race for Compassionate Use”

Earlier this month, WEP Clinical had the incredible opportunity to participate in the prestigious World Economic Forum (WEF) Davos event, as a proud sponsor of the Partner for Patient conference, HEAL - Health Equity Action [...]

By |2025-12-01T19:01:58+00:00January 28th, 2025|WEP Insights|

Why Choosing a Small Contract Research Organization (CRO) Can Elevate Your Clinical Trials

In today’s fast-paced pharmaceutical landscape, selecting the right partner for your clinical trials is crucial. Here are some compelling benefits of opting for a small CRO: Personalized AttentionSmall CROs often provide tailored solutions and dedicated [...]

By |2025-12-01T19:04:44+00:00October 23rd, 2024|WEP Insights|

Transition Management in Post-Trial and Expanded Access Programs: Navigating Change with Precision

In the world of pharmaceutical development, Expanded Access Programs (EAPs) and Post-Trial Access (PTA) initiatives play a crucial role in delivering life-saving therapies to patients in need. These programs are essential for providing access to [...]

By |2025-12-01T19:03:25+00:00October 8th, 2024|WEP Insights|